Dr Sake van Wageningen
Biology-Oncology, Astex Pharmaceuticals and Department of Molecular Carcinogenesis, The NKI (Netherlands Cancer Institute), Amsterdam
The aim of this project was to determine whether inhibition of ERN1, which is involved in the unfolded protein response, could synergize with MAPK pathway inhibitors to induce tumour cell death. CRISPR functional genomic screens were also performed in order to delineate the mechanisms by which ERN1 modulates sensitivity to MAPK inhibitors.
Sake van Wageningen is currently a Senior Scientist in Molecular Diagnostics at GenDx, The Netherlands.
Recent publications:
Xue et al., “MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models”; Cell Res. 2018 https://doi.org/10.1038/s41422-018-0044-4
Šuštić et al., “A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers”; Genome Med. 2018 https://doi.org/10.1186/s13073-018-0600-z
© Astex Pharmaceuticals
All rights reserved
